LumiraDx to be Delisted from Nasdaq: Non-Compliance with Listing Requirements
LumiraDx Limited, a UK-based diagnostics company, is facing suspension from the Nasdaq Stock Market due to its failure to comply with the exchange’s listing requirements. The company, known for its point of care diagnostic technology, has been notified of its non-compliance, specifically regarding the minimum bid price requirement, since October 2023.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
